Short Interest in Senti Biosciences, Inc. (NASDAQ:SNTI) Drops By 38.8%

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 63,600 shares, a decline of 38.8% from the December 15th total of 103,900 shares. Based on an average daily trading volume, of 2,230,000 shares, the short-interest ratio is presently 0.0 days. Currently, 2.2% of the shares of the company are short sold.

Senti Biosciences Price Performance

Senti Biosciences stock traded up $0.38 during midday trading on Thursday, hitting $4.19. The company’s stock had a trading volume of 457,682 shares, compared to its average volume of 106,567. The company has a market cap of $19.23 million, a price-to-earnings ratio of -0.27 and a beta of 2.42. Senti Biosciences has a 1-year low of $1.52 and a 1-year high of $16.94. The company has a 50-day moving average price of $3.93 and a two-hundred day moving average price of $3.01.

Analysts Set New Price Targets

Separately, Chardan Capital restated a “buy” rating and set a $10.00 price objective on shares of Senti Biosciences in a research report on Monday, December 2nd.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.